Gout and hyperuricaemia: modifiable cardiovascular risk factors?

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Hyperuricaemia and gout are linked to cardiovascular, metabolic, and renal complications.
• High prevalence of hyperuricaemia in conditions like hypertension, diabetes, and obesity exacerbates cardiovascular risk.
• Emerging evidence suggests hyperuricaemia independently promotes cardiovascular issues via inflammation, oxidative stress, and endothelial dysfunction.

Purpose of the Study:

• To review the treatment of asymptomatic hyperuricaemia regarding cardiovascular risk reduction.
• To determine optimal uric acid levels and targets for intervention.
• To discuss novel, well-tolerated treatments for lowering uric acid and preventing cardio-renal events.

Main Methods:

• Literature review of recent studies on hyperuricaemia and cardiovascular risk.
• Analysis of evidence for treating asymptomatic hyperuricaemia.
• Evaluation of new therapeutic agents like febuxostat and SGLT2 inhibitors.

Main Results:

• Evidence suggests treating hyperuricaemia may reduce cardiovascular risk, though large study data are mixed.
• New treatments like febuxostat and SGLT2 inhibitors show promise in lowering uric acid and preventing cardio-renal events.
• These agents are generally well-tolerated and offer a new approach to managing hyperuricaemia.

Conclusions:

• The management of asymptomatic hyperuricaemia is a critical area for cardiovascular risk reduction.
• Further research is needed to solidify guidelines for intervention thresholds and targets.
• Novel therapies offer effective and safe options for patients with hyperuricaemia, gout, and cardio-renal concerns.